PyData Berlin 2018 will be taking place this weekend. I will be in attendance and, on Saturday, will present a talk on AI in Healthcare.
The abstract I submitted is woefully inadequate. Luckily, I was able to write a more coherent description in the message to the organisers and they were gracious enough to accept me.
I will be talking about my main hobby-topic: why you can’t just throw the current black-box methods at biological problems and expect it to work out.
The talk is the same as one I gave as a keynote in private session at the Digital Health Forum of the Berlin Institute of Health (BIH), in March. The feedback from the BIH was so positive that I wanted to open this topic up to a wider audience (this version will also have a video posted online).
I will write up the talk as an article and post it here in a week or so.
Did you know that the development of new drugs has been unprofitable since 2005? (article, original study) I knew we were approaching that point, but I didn’t realise that we had already passed the threshold 13 years ago.
I have an insight which will completely disrupt (transform) the pharma industry. I have the background of working in two different domains in order to give credibility to my insight. And I have the ability, on a technical level, to execute on it.
How many of you have heard this pitch before? Continue reading “Designing a Disruptive Technology”
Having worked in two traditionally distinct fields, both separately and combining the methods of both, I have more than a few thoughts on what separates these disciplines and how this can be quite detrimental.
As I see it there are two core differences between a mathematical world-view and a biological one: the first is in how knowledge is acquired; and the other is the difference between a dynamical world-view and a static one. What may surprise you is which one is static and which one is dynamic!
Continue reading “Mathematics and Biology”
A number of stellar academics made minor headlines, in 2016-17, by publishing CVs of their failures. This had an initial, and intended, positive effect. Many early-stage researchers marvelled at the bravery of Stanford-level professors being willing to open-up about the unsuccessful pathways which they had followed earlier in their careers. Some of those writing their admissions even argued that their current CV would not get them a real job, outside of academia.
A natural, if gentle, backlash set-in pretty quickly. It’s all very well for successful associate or tenure-track professors to open-up and reveal their inner worries. But they are doing this from a position of incredible privilege. Would it really break down any barriers to reveal that the British royal family have worries about health and relationships and money too? Of course not! It softens their public image in some eyes; it humanises them. But it does not change the fact that they are revealing that even people with privilege have mundane worries too. If you have risen to tenure-track at a top American university you have joined the privileged classes, even if you did not start out that way. Your contribution to society may be in opening up new access to the elites, but it is not in admitting that the elites also fail sometimes.
I was very tempted at the time, to join the rush, and post my own CV of failure. I wanted Continue reading “Shame”
my first real startup. That is, the first time that I’ve actually incorporated a company. Simmunology Limited exists since last week.
The path to incorporation has been an interesting and sometimes terrifying ride. (Aside: understatement will typically be an element of my style, this should be borne in mind when reading my prose.) I finished up a postdoc in computational neuroscience at TU Berlin last December (2017). Since then I have been trying to establish a place for myself in the world in which I get to use my, not inconsiderable, experience to choose my own directions.
I left academia with a strong feeling that not-all is right in the academic world. In fact it is very, very wrong. But more importantly, I don’t think that the kind of cross-disciplinary talents which I bring to the table will ever be fully utilised in that sector, at least not as it exists today.
I came up with two pet projects which I thought I could work on to bring an impact to the world. The first, Continue reading “Simmunology is….”